Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Impel NeuroPharma (NASDAQ: IMPL) shares are down premarket on Friday after it announced its $45 million public offering pricing.
The company is offering 3 million shares of its stock at a price of $15 per share. Before deducting expenses, the gross proceeds from the offering are expected to be $45.0 million.
In addition, Impel has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of stock at the offering price. The offering is expected to close on September 14.
Cowen and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.
Thursday saw the company's shares gain 27.25%, closing at $21.13 a day after it announced the public offering.
However, premarket on Friday has seen Impel shares resume their fall, currently trading at $18.35, down 13.87%
Only last week, Cowen analyst Ken Cacciatore raised the firm's price target on Impel NeuroPharma to $55 from $35, keeping an Outperform rating.
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .